Beam Therapeutics (BEAM) Common Equity (2019 - 2026)

Beam Therapeutics (BEAM) has reported Common Equity for 8 consecutive years, with $1.2 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Common Equity rose 3.1% year-over-year to $1.2 billion; the TTM figure through Mar 2026 stood at $1.2 billion (up 3.1% YoY), while the FY2025 annual figure was $1.2 billion, up 68.82% from the prior year.
• Common Equity eased to $1.2 billion in Q1 2026 per BEAM's latest filing, from $1.2 billion in the prior quarter.
• Across five years, Common Equity topped out at $1.2 billion in Q4 2025 and bottomed at $714.5 million in Q3 2022.
• Historically, Common Equity has averaged $896.9 million across 5 years, with a median of $829.1 million in 2022.
• Annual changes were most pronounced in 2022 — Common Equity jumped 96.26% — and 2024, when it decreased 25.25%.
• Beam Therapeutics' Common Equity stood at $733.5 million in 2022, then surged by 33.79% to $981.3 million in 2023, then fell by 25.25% to $733.5 million in 2024, then soared by 68.82% to $1.2 billion in 2025, then declined by 5.97% to $1.2 billion in 2026.
• Business Quant data shows BEAM's Common Equity at $1.2 billion in Q1 2026, $1.2 billion in Q4 2025, and $966.0 million in Q3 2025.